For gastrointestinal, non-midgut NEN, SSA and everolimus can be used as for pancreatic NEN, while the SSA coverage can be expanded to tumors with a larger tumor burden or higher Ki-67 index for midgut NEN due to its indolent behavior [50]. This evidence concerns the gene MKI67 and neoplasm.